ABSTRACT
This entry focuses on orphan drugs for rare diseases. It provides background on the issues description of the Orphan Drug Law enacted in 1983 to address these issues, an accounting of progress to date emanating from the Law’s enactment, and a discussion of remaining or new issues related to orphan drugs.
